Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

The website for the popular JDownloader download manager was compromised earlier this week to distribute malicious Windows and Linux installers, with the Windows payload found deploying a Python-based ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

At its core, ChatGPT is a glorified search engine. But it offers a variety of other useful features as well. While you should never take its output as gospel without a quick fact-check, the platform ...

A SYSTEM DESIGNED to predict the most likely next word in a sentence can also write good computer code, offer strategic advice and respond with remarkable empathy to human problems. We don’t fully ...

Burmese pythons are an invasive species in South Florida, originally from Southeast Asia and introduced through the pet trade. The non-venomous constrictors disrupt the ecosystem by preying on native ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Sorry to burst your bubble right off the bat, but the show hasn’t even been renewed yet. While Welcome to Derry had a strong start, that number quickly fell off in subsequent episodes. That said, it’s ...

This advanced version of the Google IT Support certificate teaches learners how to automate IT tasks using Python, Git and IT tools. The program includes hands-on exercises for scripting, system ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...